Denzime
Amgen joins M&A rush with deals for Dezima and Xencor
September 16, 2015Research and Development, Sales and Marketing Amgen, Cancer, Denzime, Xencor, cardiovascular disease, high cholesterol, inflammation
Amgen has struck deals that could potentially be worth $3.25 billion, to purchase the Dutch firm Dezima and kick-off a …
Latest content
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
